A Research Codex ~ Chapter VI
TB-500 FAQ: The Questions, Answered From the Record
Direct answers on mechanism, safety, evidence, and standing — each sealed to a study, each preserving the fragment-versus-parent distinction.
Frequently asked questions about TB-500
These TB-500 questions are answered from the published record, with each quantitative claim sealed to a study. Where a finding used full-length thymosin beta-4 rather than the Ac-LKKTETQ fragment, the answer says so.
What is TB-500?
TB-500 is the synthetic, N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 — the actin-binding motif — of the 43-amino-acid protein thymosin beta-4 [9]. It is a research and veterinary-context peptide with no approved human therapeutic indication. Most published efficacy data are for the full-length parent protein, not the seven-residue fragment.
What does TB-500 stand for and what does TB stand for in TB-500?
The "TB" references thymosin beta-4, the parent protein; "TB-500" is a research and veterinary designation for the synthetic Ac-LKKTETQ fragment of that protein [9]. It is not an abbreviation with a formal expansion beyond the thymosin-beta lineage. The name marks ancestry, not an indication or an approved use.
What is TB-500 used for in research?
In animal and in vitro research, thymosin beta-4 and its actin-binding region are studied for wound re-epithelialization, tissue repair, angiogenesis, anti-inflammatory and anti-fibrotic remodeling, and cardiac and neurological repair [5]. Human efficacy of the fragment is unproven, and no completed controlled human trial of the heptapeptide exists for any of these uses.
How does TB-500 work?
TB-500 carries the LKKTETQ actin-binding motif of thymosin beta-4. The parent protein binds monomeric (G-) actin in a 1:1 complex, capping both ends of the monomer to buffer the unpolymerized pool and regulate cytoskeletal dynamics, cell migration, angiogenesis, and anti-inflammatory signaling [1][5]. Whether the isolated heptapeptide reproduces this at peptide-research doses is unproven in humans.
Does TB-500 reduce inflammation?
Full-length thymosin beta-4 suppressed TNF-alpha-induced NF-kB activation and, in recent animal models, modulated tissue inflammatory responses; a 2024 study links its effects to specialized pro-resolving pathways [14]. Whether the isolated heptapeptide reproduces this is unproven, and there is no human anti-inflammatory trial of the TB-500 fragment.
Can TB-500 cause autoimmune reactions or affect the immune system?
No autoimmune signal is established for the heptapeptide. Thymosin beta-4 modulates inflammation and was associated with pro-resolving pathways in a 2024 study [14], and the intravenous Phase 1 study of full-length thymosin beta-4 in healthy volunteers reported no serious adverse events to 1260 mg [6]. The FDA's Category 2 placement does cite potential immunogenicity for certain routes as a concern [16].
Does TB-500 work for muscle tears and recovery from exercise?
A 2026 Sports Medicine review lists TB-500 among unapproved peptides with favorable animal-model tissue-repair outcomes but scarce human safety data and no regulatory approval [10]. No controlled human trial supports muscle-recovery claims for the fragment, and a chronic mdx-mouse study increased regenerating fibers without improving muscle strength [10].
Does TB-500 cause cancer or promote tumor growth?
Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so the pro-migratory, pro-angiogenic properties that aid repair are a theoretical oncologic concern [10]. Human safety data for the fragment are scarce, and this unresolved signal is the central reason chronic-use safety cannot be assumed.
How long does it take for TB-500 to work for injury healing?
No human healing timeline is established for the fragment. In a rat full-thickness wound model, thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline [3]. Those are animal figures for the parent protein; human-use timelines for TB-500 are not validated.
Can TB-500 help with tendon injuries and ligament repair?
Connective-tissue repair is part of the research rationale, but a 2026 Sports Medicine review classes TB-500 among unapproved peptides whose human safety data are scarce and which lack regulatory approval [10]. No controlled human tendon or ligament trial of the fragment exists.
Does TB-500 affect the heart?
In mice, thymosin beta-4 activated the PINCH-ILK-Akt survival pathway and improved cardiac function after coronary ligation [2], and recent work uses engineered local delivery to promote cardiac repair [15]. Some models showed no benefit [10], and human cardiac efficacy of the fragment is unproven.
Does TB-500 promote angiogenesis and is that a safety concern?
Thymosin beta-4 is pro-angiogenic, driving endothelial migration and vessel formation, which aids repair [5] but is also a theoretical tumor-progression concern, since the same pathways can support metastasis [10]. Human safety data for the fragment are limited.
Does TB-500 have neuroprotective effects on the brain?
In a rat embolic-stroke dose-response study, intraperitoneal thymosin beta-4 improved neurological function at 2 and 12 mg/kg but not at 18 mg/kg, with a modeled optimal near 3.75 mg/kg [4]. These are animal data; an injectable thymosin beta-4 acute-stroke human trial was withdrawn.
TB-500 Side Effects and Safety Signals in the Literature
The TB-500 side effects question has no controlled human answer for the fragment, so this codex reads the safety record from the parent protein and from the regulatory standing. Two signals frame it. First, tolerability: intravenous full-length thymosin beta-4 was well tolerated to 1260 mg across a 14-day Phase 1 study, with only infrequent mild or moderate adverse events and no dose-limiting toxicities [6]. Second, and more weighty, the unresolved concern: thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so its pro-migratory, pro-angiogenic biology is a theoretical oncologic signal [10]. The FDA's own Category 2 rationale cites potential immunogenicity for certain routes and a lack of important safety information [16]. The questions below answer the specific safety queries in turn.
What are the side effects of TB-500?
No controlled side-effect profile exists for the heptapeptide. Intravenous full-length thymosin beta-4 was well tolerated to 1260 mg in a Phase 1 study, with only infrequent mild or moderate events and no dose-limiting toxicities [6]. The main theoretical concern is the tumor and angiogenesis signal of thymosin beta-4 [10].
Does TB-500 help wound healing?
In a rat full-thickness wound model, thymosin beta-4 increased re-epithelialization (+42% at four days, up to +61% at seven days), wound contraction, and collagen and angiogenesis [3]; clinical-grade topical thymosin beta-4 (RGN-259) promoted corneal healing in trials [8]. Fragment efficacy in humans is unproven.
What is the difference between TB-500 and BPC-157?
They are distinct peptides studied for tissue repair; a 2026 Sports Medicine review lists both among unapproved peptides with animal-model promise but scarce human safety data and no regulatory approval [10]. This codex summarizes research; it does not compare products or rank sources.
Is TB-500 safe for long-term use?
Long-term human safety of the fragment is unstudied. The only multi-dose human data are 14 days of intravenous full-length thymosin beta-4, well tolerated to 1260 mg [6]. The unresolved tumor and angiogenesis signal of thymosin beta-4 makes chronic-use safety claims unsupported [10].
Is TB-500 FDA approved?
No. TB-500 has no FDA-approved therapeutic indication and is not an FDA-approved drug; the FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 in its September 29, 2023 update [16]. The only human data are for full-length thymosin beta-4 — a Phase 1 intravenous study [6] and topical ophthalmic work [8].
Is TB-500 banned by WADA and in competitive sports?
Yes. TB-500 and thymosin beta-4 fall under WADA's prohibited peptide, growth-factor, and tissue-repair categories, banned in and out of competition, and are detected by LC-MS anti-doping assays in equine and human samples [9]. The fragment's chemistry was first characterized as a doping-control reference [9].
Is TB-500 legal?
TB-500 has no FDA-approved human indication and is not within the FDA's enforcement-discretion policy for 503A compounding as a Category 2 substance [16]; it is sold by research suppliers for laboratory use and is WADA-prohibited in sport [9]. Some jurisdictions classify it as a prescription medicine. See the TB-500 legal status chapter for the full standing.
Can you get TB-500 from a compounding pharmacy?
Compounding-pharmacy access for this peptide is constrained by the FDA bulk-drug-substance review process: a compounder may use an ingredient only if it is eligible under the 503A/503B rules, and a Category 2 substance is not eligible for routine 503A compounding while that status stands [16][18]. See the FDA 503A compounding access discussion for the lawful pathway in general terms.
What is the FDA 503A status of TB-500?
The FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — bulk substances that may present significant safety risks — effective with the September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information [16]. It is also listed for discussion at the scheduled July 23-24, 2026 PCAC meeting, which is an evaluation step, not a decision [17].
Why is TB-500 used in racehorses?
TB-500 was encountered as a designer peptide in equine sport, prompting the first LC-MS detection method in horses, with reported limits of detection of 0.01 to 0.02 ng/mL [9]. It is supplied as a veterinary-context preparation of the synthetic Ac-LKKTETQ fragment and is a doping-control target, not an approved equine therapeutic.
Are there any human clinical trials on TB-500?
There are no completed controlled trials of the TB-500 heptapeptide for any indication. Human data exist only for full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous study, well tolerated to 1260 mg [6], and topical and ophthalmic thymosin beta-4 (RGN-259) [8]. An early injectable acute-stroke trial was withdrawn.